One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)
For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies; chronic simple (open-angle) glaucoma
Samara state medical university, Samara, Russian Federation
UC San Diego; Altman Clinical and Translational Research Institute Building, La Jolla, California, United States
UC San Diego; Altman Clinical and Translational Research Institute Building, La Jolla, California, United States
Brigham and Women's Hospital, Boston, Massachusetts, United States
John D. Dingell VA Medical Center, Detroit, MI, Detroit, Michigan, United States
University of Waterloo, Waterloo, Ontario, Canada
UC San Diego Altman Clinical & Translational Research Institute, La Jolla, California, United States
MD Anderson Cancer Center, Houston, Texas, United States
Jessa Hospital, Hasselt, Limburg, Belgium
University Hospital Brussels, Jette, Brussels, Belgium
USARIEM, Natick, Massachusetts, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.